Table 1—

Demographic, clinical and routine laboratory data of the study population

ControlARDS all patientsPrimary ARDSSecondary ARDS
Subjects n2040319
Age yrs28.1±1.354.3±2.3***55.9±2.8***48.9±3.3***
Sex F/M10/1017/2313/184/5
Pa,O2/FI,O2 mmHg455.1±15.1143.0±9.0***134.0±9.1***170.2±22.2***
Patients alive on day 2830 (75.0)23 (74.2)7 (77.8)
BALF recovery %79.7±2.258.8±2.5***57.1±2.6***64.1±6.1*
Neutrophils %1.1±0.255.2±4.3***54.0±5.6***59.0±4.7***
Lymphocytes %4.4±0.78.8±2.510.3±3.34.2±1.1
Macrophages %94.5±0.636.0±3.5***35.7±4.5***36.8±4.9***
PL µg·ml−131.8±3.727.2±2.825.4±3.333.2±5.4
Protein mg·ml−10.07±0.001.04±0.12***1.09±0.21***0.94±0.32***
PPQ0.460±0.0280.042±0.009***0.035±0.007***0.063±0.029***
  • Data are presented as n, mean±sem and n (%). Acute respiratory distress syndrome (ARDS) patients were further divided into primary and secondary ARDS. F: female; M: male; Pa,O2: arterial oxygen tension; FI,O2: inspiratory oxygen fraction; BALF: bronchoalveolar lavage fluid; PL: total phospholipids in BALF; protein: total protein in BALF; PPQ: phospholipid-protein ratio. *: p<0.05; ***: p<0.001. 1 kPa=0.133 mmHg